Research programme: intranasal therapeutics - West Pharmaceuticals

Drug Profile

Research programme: intranasal therapeutics - West Pharmaceuticals

Alternative Names: Granisetron intranasal - West Pharmaceuticals; Ketoprofen intranasal - West Pharmaceuticals; Morphine-6-glucuronide intranasal - West Pharmaceuticals; NSAID intranasal - West Pharmaceuticals; Zolpidem intranasal - West Pharmaceuticals

Latest Information Update: 04 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator West Pharmaceutical Services
  • Class
  • Mechanism of Action GABA A receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia; Nausea and vomiting; Pain

Most Recent Events

  • 14 Dec 2004 This programme is available for licensing (http://www.westpharma.com)
  • 14 Dec 2004 Preclinical trials in Emesis in USA (Intranasal)
  • 14 Dec 2004 Preclinical trials in Insomnia in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top